Review
Cardiac & Cardiovascular Systems
Alpo Vuorio, Frederick Raal, Markku Kaste, Petri T. Kovanen
Summary: Patients with familial hypercholesterolemia (FH) are at increased risk for COVID-19 complications, with a focus on lowering LDL-C levels through statin use to mitigate cardiovascular risks. Epidemiologic data on FH patients and COVID-19 severity are needed to understand the increased risk and severity of infections.
Article
Cardiac & Cardiovascular Systems
C. de Roquetaillade, B. G. Chousterman, D. Tomasoni, M. Zeitouni, E. Houdart, A. Guedon, P. Reiner, R. Bordier, E. Gayat, G. Montalescot, M. Metra, A. Mebazaa
Summary: A study found that arterial thromboembolic events occur in a small proportion of COVID-19 patients, but may be underestimated. These events include acute coronary occlusions, stroke, limb ischemia, and more. Further research is needed to determine the exact incidence and best prevention methods.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Alpo Vuorio, Frederick Raal, Petri T. Kovanen
Summary: Heterozygous familial hypercholesterolemia (HeFH) patients have a higher risk of acute myocardial infarction (AMI) and ischemic stroke during and after SARS-CoV-2 infection. The pre-existing endothelial dysfunction and early-onset atherosclerosis in HeFH patients make them more susceptible to the direct and indirect damage caused by the virus. Effective cholesterol lowering treatment is crucial in preventing or alleviating the detrimental effects of SARS-CoV-2 infection among HeFH patients.
REVIEWS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Multidisciplinary Sciences
Lan Shen, Lin Qiu, Li Wang, Hengye Huang, Dong Liu, Ying Xiao, Yi Liu, Jingjin Jin, Xiulan Liu, Dao Wen Wang, Ben He, Ning Zhou
Summary: The study found that the use of statins can reduce the risk of in-hospital mortality in COVID-19 patients, especially among patients with coronary heart disease, indicating that the continued use of statins may be beneficial for COVID-19 patients.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Ellinor Peerschke, Alisa Valentino, Rachel J. So, Scott Shulman, Ravinder
Summary: The study found that cancer patients with COVID-19 exhibit circulating markers of endothelial cell dysfunction, platelet activation, and systemic inflammation. Furthermore, complement activation in cancer patients with COVID-19 increases significantly in the presence of thromboinflammation, indicating a possible link between coagulation and complement cascades during inflammation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Cristina Rodriguez, Neus Luque, Isabel Blanco, Laura Sebastian, Joan Albert Barbera, Victor Peinado, Olga Tura-Ceide
Summary: SARS-CoV-2, causing COVID-19, poses a major threat to global public health with severe respiratory and multiorgan complications. The complications of COVID-19, including cytokine storm and thrombi formation, involve the pulmonary endothelium in regulating vascular homeostasis and coagulation.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Marie-Agnes Dragon-Durey, Xiaoyi Chen, Amos Kirilovsky, Nadine Ben Hamouda, Carine El Sissy, Jules Russick, Etienne Charpentier, Yannick Binois, Florence Marliot, Maxime Meylan, Clemence Granier, Helene Pere, Antonin Saldmann, Bastien Rance, Anne Sophie Jannot, Stephanie Baron, Mouna Chebbi, Antoine Fayol, Nathalie Josseaume, Claire Rives-Lange, Pierre-Louis Tharaux, Bernard Cholley, Jean-Luc Diehl, Jean-Benoit Arlet, Michel Azizi, Alexandre Karras, Sebastien Czernichow, David M. Smadja, Jean-Sebastien Hulot, Isabelle Cremer, Eric Tartour, Elie Mousseaux, Franck Pages
Summary: This study investigated the mechanisms underlying SARS-CoV-2 infection severity in patients with obesity. It found specific associations between inflammatory cytokines and liver, renal, and endothelial dysfunctions in obese patients, and independent correlations between early lung damage and obesity with cytokine levels. These findings highlight distinct pathophysiological mechanisms associated with SARS-CoV-2 infection in obese patients.
Article
Medicine, General & Internal
Camille Chenevier-Gobeaux, Morgane Ducastel, Jean-Francois Meritet, Yassine Ballaa, Nicolas Chapuis, Frederic Pene, Nicolas Carlier, Nicolas Roche, Tali-Anne Szwebel, Benjamin Terrier, Didier Borderie
Summary: This study found that endocan is associated with thrombotic events in COVID-19 patients and may serve as a useful biomarker. Endocan concentrations increased with the severity of the disease, and patients experiencing thrombotic events had significantly higher levels of endocan. Combining endocan measurement with D-dimers improved the identification of thrombotic events. The combination of endocan and D-dimers better discriminated patients with thrombotic events. The combination of D-dimers and endocan was independently associated with thrombotic events.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Alpo Vuorio, Frederick Raal, Petri T. T. Kovanen
Summary: Patients with heterozygous familial hypercholesterolemia (HeFH) are at increased risk for COVID-19 cardiovascular complications due to elevated levels of LDL-C and lipoprotein(a), which lead to endothelial dysfunction and are aggravated by viral attack and exposure to proinflammatory and prothrombotic mediators during the hyperinflammatory reaction of COVID-19.
CURRENT OPINION IN LIPIDOLOGY
(2023)
Article
Medicine, General & Internal
Maurizio G. Abrignani, Adriano Murrone, Leonardo De Luca, Loris Roncon, Andrea Di Lenarda, Serafina Valente, Pasquale Caldarola, Carmine Riccio, Fabrizio Oliva, Michele M. Gulizia, Domenico Gabrielli, Furio Colivicchi
Summary: The coronavirus disease 2019 (COVID-19) is associated with cardiovascular complications, including venous and arterial thromboembolic events. Vaccines coding for the spike protein are used to prevent COVID-19. However, there have been reports of thrombotic events, especially in fertile women, in subjects who received adenovirus-based vaccines.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Gregory C. Piazza, Alex Spyropoulos, Judith Hsia, Mark J. Goldin, William S. Towner, Alan M. Go, Todd Bull, Stephen Weng, Concetta S. Lipardi, Elliot P. Barnathan, Marc Bonaca
Summary: This study aimed to assess the effectiveness of anticoagulation treatment in nonhospitalized COVID-19 patients. The results showed that using rivaroxaban for 35 days did not reduce the incidence of venous and arterial thrombotic events, hospitalization, and death in COVID-19 patients at risk for thrombosis.
Article
Medicine, Research & Experimental
Patrice Marques, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervas, Juan F. Ascaso, Laura Piqueras, Jose T. Real, Maria-Jesus Sanz
Summary: Inhibiting PCSK9 function can impact systemic inflammation and endothelial dysfunction by constraining leukocyte-endothelium interactions, enhancing T-regulatory cell activation, and reducing inflammatory response.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Medicine, General & Internal
Morgane Fournier, Dorothee Faille, Antoine Dossier, Arthur Mageau, Pascale Nicaise Roland, Nadine Ajzenberg, Raphael Borie, Lila Bouadma, Vincent Bunel, Yves Castier, Christophe Choquet, Bruno Crestani, Eric Daugas, Laurene Deconinck, Diane Descamps, Vincent Descamps, Philippe Dieude, Gregory Ducrocq, Nathalie Faucher, Tiphaine Goulenok, Celine Guidoux, Antoine Khalil, Philippa Lavallee, Francois Xavier Lescure, Brice Lortat-Jacob, Herve Mal, Pierre Mutuon, Quentin Pellenc, Philippe Gabriel Steg, Camille Taille, Jean Francois Timsit, Yazdan Yazdanpanah, Thomas Papo, Karim Sacre
Summary: This study evaluated the clinical course and risk factors for arterial thrombotic events in adult inpatients with COVID-19. Results showed that 5.6% of COVID-19 patients experienced arterial thrombotic events, which were associated with atypical patterns and increased in-hospital mortality rate. A D-dimer level above 1250 ng/mL may identify patients at risk for arterial thrombotic events.
MAYO CLINIC PROCEEDINGS
(2021)
Letter
Hematology
Charles Esenwa, Santiago R. Unda, David J. Altschul, Nikunj K. Patel, Avinash Malaviya, Johanna Seiden, Andrea Lendaris, Khadean Moncrieffe, Daniel L. Labovitz
Summary: The study found that there were no significant differences in thrombotic events among different racial groups of hospitalized COVID-19 patients, suggesting that racial disparities related to COVID-19, specifically thrombotic complications, may not be caused by biological differences based on race.
THROMBOSIS RESEARCH
(2021)
Review
Immunology
Christian A. Devaux, Laurence Camoin-Jau, Jean-Louis Mege, Didier Raoult
Summary: Elevated antiphospholipid antibodies have been found in many COVID-19 patients, suggesting a link to antiphospholipid syndrome. Hydroxychloroquine, known for its antithrombotic properties in APS therapy, may be a potential candidate for preventing thrombotic events in COVID-19 patients. Further evaluation of its repurposing is warranted.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2021)
